立即注册 登录
蒲公英 - 制药技术的传播者 GMP理论的实践者 返回首页

jyzou1976的个人空间 https://yx.ouryao.com/?25782 [收藏] [复制] [分享] [RSS]

日志

OOS, Complaints also need CAPA Plans

已有 632 次阅读2020-11-4 10:31 |个人分类:法规

Some companies still might thing that only deviations lead to corrective and preventive actions (CAPA). But that is not true. A recent Warning Letter issued by the FDA is picking this up now. An Indian pharmaceutical company manufacturing sterile injectables and solid dosage drug products did conduct out-of-specification (OOS) and complaint investigations which were not adequate, according to FDA. This was "including the identification of the root cause and timely implementation of effective corrective action and preventive action (CAPA) plans".

The FDA thought that some OOS investigations did not provide sufficient scientific justification to define the root cause. And - of course - there was criticism that as a CAPA, staff was simply retrained to avoid recurrence. Here, however, actions based on a precisely defined root cause were expected. The investigations were not detailed enough; the determination of the effectiveness of the CAPAs was unclear. Similar problems arose in the processing of complaints.

Therefore, before an organisation defines corrective and preventive actions, it is important to carry out a systematic investigation process throughout the entire chain of events to determine the true cause.

Please also see the FDA's Warning Letter to Shilpa Medicare Limited for further details.


路过

雷人

握手

鲜花

鸡蛋

评论 (0 个评论)

facelist

您需要登录后才可以评论 登录 | 立即注册

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  京ICP证150354号  互联网药品信息服务证书编号: (京)-非经营性-2024-0033

GMT+8, 2024-11-13 19:58

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
返回顶部